Company Information

    ONL Therapeutics was founded on January 2011. The company is based in Ann Arbor, MI, USA . The number of employees in ONL Therapeutics is less than 50. Onl therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors.
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          ONL Therapeutics has received 7 rounds of venture funding. The total funding amount is around $57.9M. Last venture funding round was $46.9M, announced on December, 2020.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        ONL Therapeutics - Blog

                          • ONL Therapeutics Names Connie Chang as Chief Operating Officer

                          • Company expands leadership team as it advances lead candidate ONL1204 beyond retinal detachment into the chronic conditions of glaucoma and dry age-related macular degeneration ANN ARBOR, MI – January 19, 2021 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Connie […]
                          • ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications

                          • Beyond retinal detachment, lead candidate ONL1204 will also advance into the chronic conditions of glaucoma and dry age-related macular degeneration over the next 24 months ANN ARBOR, MI – December 22, 2020 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced it closed on […]
                          • ONL Therapeutics featured on the OIS Retina Podcast

                          • ANN ARBOR, MI – June 30, 2020 This week’s special guest on the OIS Retina Podcast is David Esposito, CEO of ONL Therapeutics. A West Point graduate who served as a platoon leader in the first Gulf War, Esposito began his career in ophthalmology as a pharmaceutical sales rep for Merck. This led to several executive positions and […]
                          • ONL Therapeutics Announces First Patient Treated in Phase I Study With ONL1204

                          • ONL Therapeutics transformed into a clinical stage biopharmaceutical company with first-in-human study ANN ARBOR, MI – October 23, 2019 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the first patient has been treated in the company’s First-in-Human trial with its lead drug […]
                          • ONL Therapeutics Announces First-in-human Clinical Study With ONL1204

                          • Lead candidate ONL1204 advances into Phase I clinical study in retinal detachment in Australia ANN ARBOR, MI – October 8, 2019 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the initiation of the company’s First-in-Human trial with its lead drug candidate ONL1204. The […]

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *